Literatur
Veltassa®
Report adverse events:
Adverse events should be reported to the Vifor Pharma group.
safety@viforpharma.com
Literatur
Agarwal R, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394(10208):1540−50.
Bakris GL, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA 2015;314(2):151−61.
Bandak G, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc 2017;6(7):e005428.
Betts KA, et al. The Cost of Hyperkalemia in the United States. Kidney Int Rep 2018;3(2):385−93.
Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861−9.
Bushinsky DA, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015;88(6):1427−33.
Bushinsky DA, et al. Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. Clin J Am Soc Nephrol 2016;11(10):1769−76.
Clase CM, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020;97(1):42−61.
Collins AJ, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol 2017;46(3):213−21.
Dasgupta A. Third in a series on hyperkalemia: current views on the treatment of hyperkalemia. E-Journal of Cardiology Practice 2016;14, No 13. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/fourteen-thirteen.
Desai AS, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007;50(20):1959−66.
Desai NR, et al. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. PLoS One 2020 Jan 7;15(1):e0226844. doi: 10.1371/journal.pone.0226844.
Di Lullo L, et al. Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options. Cardiorenal Med 2019;9(1):8−21.
Dunn JD, et al. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care 2015;21(15 Suppl):S307−S315.
Einhorn LM, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169(12):1156−62.
Epstein M, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(11 Suppl): S212−S220.
Fachinformation Resonium A®: www.swissmedicinfo.ch.
Fachinformation Sorbisterit®: www.swissmedicinfo.ch.
Fachinformation Veltassa®: www.swissmedicinfo.ch .
Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int 2018;93(2):325−34.
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355(9200):253−9.
Ishikawa S, et al. Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. PLOS One 2018;13:1–16.
Kapelios CJ, et al. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020; doi: 10.1002/ejhf.1796.
Kashihara N, et al. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney Int Rep 2019;4(9):1248−60.
KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(Suppl 4S):S1–S116.
KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1–150. .
Kim GH. Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease. Electrolyte Blood Press 2019;17(1):1−6.
Kjeldsen KP, Schmidt TA. Potassium homoeostasis and pathophysiology of hyperkalaemia. Eur Heart J 2019;21(Suppl A):A2−A5.
Komajda M, et al. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail 2016;18(5):514−22.
Kovesdy CP, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J 2018;39(17):1535−42.
Kovesdy CP, et al. Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med 2020;132:176–83.
Kraft MD, et al. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005;62(16):1663−82.
Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851−60.
Li L, et al. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia. J Cardiovasc Pharmacol Ther 2016;21(5):456−65.
Lindenfeld J, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16(6):e1−e194.
Lund LH, Pitt B. Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use. Eur J Heart Fail 2018;20:931–2.
Luo J, et al. Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. Clin J Am Soc Nephrol 2016;11(1):90−100.
Martens P, et al. Heart failure is associated with accelerated age related metabolic bone disease85.2020.1771885. Acta Cardiol 2020; doi: 10.1080/00015385.2020.1771885.
Mathialahan T, et al. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol 2005;206:46−51.
McDonagh, Theresa A et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal vol. 42,36 (2021): 3599-3726. doi:10.1093/eurheartj/ehab368
McMurray JJ, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993−1004.
Montford JR, Linas S. How Dangerous Is Hyperkalemia?. J Am Soc Nephrol 2017;28(11):3155−65.
National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. 2014. Available at: http://www.nice.org.uk/CG182 (accessed April 2020).
National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. 2004. Available at: kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bp/index.htm (accessed July 2020).
National Kidney Foundation. The DASH Diet. Available at: kidney.org/atoz/content/Dash_Diet (accessed July 2020).
Nilsson E, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol 2017;245:277−84.
Noureddine L, Dixon BS. Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer. Clin Invest (Lond) 2015;5(10):805−23.
Núñez J, et al. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. Circulation 2018;137:1320–30.
Ouwerkerk W, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 2017;38(24):1883−90.
Palmer BF, et al. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585–92.
Palmer BF. In: Kimmel PL, Rosenberg M (Eds). Chronic Renal Disease . 2015:386−7.
Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol 2015;10(6):1050−60.
Palmer SC, et al. Dietary interventions for adults with chronic kidney disease. Cochrane Database Syst Rev 2017;4:CD011998.
Pitt B, et al. Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Fail 2018;5(4):592−602.
Pitt B, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32(7):820−8.
Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709−17.
Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18(8):891−975.
Provenzano M, et al. Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care. J Clin Med 2018;7:499. DOI:10.3390/jcm7120499.
Qiao Y, et al. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 2020;180(5):718−26.
Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J 2001;77(914):759−64.
Rosano GMC, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 2018;4(3):180−8.
Rossignol P, et al. Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review. Clin Kidney J 2020;13:714−9.
Sandle GI. Salt and water absorption in the human colon: a modern appraisal. Gut 1998;43(2):294−9.
Savarese G, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail 2019;7(1):65−76.
Seferovic PM, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:1169–86.
Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003;138(11):917−24.
Solomon SD, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019;381(17):1609−20.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293−302.
Ter Maaten JM, et al. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol 2020;109(8):1048−59.
The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;28;349(9069):1857−63.
Thomsen RW, et al. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. J Am Heart Assoc 2018;7(11):e008912.
Trevisan M, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 2018;20(8):1217−26.
Tromp J, van der Meer P. Hyperkalaemia: aetiology, epidemiology, and clinical significance. Eur Heart J 2019;21(Suppl A):A6−A11.
Vendramini LC, et al. Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res 2012;45(9):834−40.
Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372(3):211−21.
Welch A, et al. Hyperkalemia: getting to the heart of the matter. Nephrol Dial Transplant 2013;28(1):15−16.
Yancy CW, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017;136(6):e137−e161.
Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147−e239.
Yildirim T, et al. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern?. Ren Fail 2012;34(9):1095−9.
Youn JH, McDonough AA. Recent advances in understanding integrative control of potassium homeostasis. Annu Rev Physiol 2009;71:381−401.
Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21.
Die Fachpersonen können bei Vifor Pharma Schweiz eine vollständige Kopie des zitierten Prüfungsberichts anfordern.
Contact a Vifor medical representative
To learn more about hyperkalaemia management with Veltassa®, please contact us.
Address
Veltassa
Rechenstrasse 37,
9014 St. Gallen,
Switzerland
Stay in touch
Keep up to date on social media or
Contact us with any other Information
T: +41 (0) 58 851 8000
F: +41 (0) 58 851 8001
medinfo@viforpharma.com
Sign up for alerts
Be notified of any news, reports or
updates straight to your email address
The information and materials for Veltassa contained in this website were prepared based on the EU SmPC. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd, a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and 0M Pharma. For more information about Vifor Pharma, please visit www.viforpharma.com
This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site’s accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2019 Vifor Fresenius Medical Care Renal Pharma
HQ-PAT-2000046 | Date of preparation: December 2020